{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:33:13Z","timestamp":1790299993214,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40263-024-01097-w","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:08:54Z","timestamp":1717592934000},"page":"493-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"38","author":[{"given":"Michael H.","family":"Rosenbloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"O\u2019Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domi","family":"Zhou-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepashni","family":"Mala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Modrijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melora","family":"Riveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darla","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Shakalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"1097_CR1","first-page":"362","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"1097_CR2","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598\u2013695.","DOI":"10.1002\/alz.13016"},{"key":"1097_CR3","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. 2023;101:e1837\u201349.","journal-title":"Neurology"},{"key":"1097_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamaneurol.2023.0123","volume":"80","author":"DA Wolk","year":"2023","unstructured":"Wolk DA, Rabinovici GD, Dickerson BC. A step forward in the fight against dementia\u2014are we there yet? JAMA Neurol. 2023;80:429\u201330.","journal-title":"JAMA Neurol"},{"key":"1097_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1097_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","volume":"56","author":"DS Knopman","year":"2001","unstructured":"Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143\u201353.","journal-title":"Neurology"},{"key":"1097_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13024-023-00637-0","volume":"18","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Day GS. Anti-amyloid therapies for Alzheimer disease: finally, good news for patients. Mol Neurodegener. 2023;18:42.","journal-title":"Mol Neurodegener"},{"key":"1097_CR8","first-page":"771","volume":"10","author":"S Cohen","year":"2023","unstructured":"Cohen S, van Dyck CH, Gee M, et al. Lecanemab Clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2023;10:771\u20137.","journal-title":"J Prev Alzheimers Dis"},{"key":"1097_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler SE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395.","journal-title":"Nat Med"},{"key":"1097_CR10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A PichetBinette","year":"2023","unstructured":"PichetBinette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19:1403\u201314.","journal-title":"Alzheimers Dement"},{"key":"1097_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barthelemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;80:516\u201322.","journal-title":"JAMA Neurol"},{"key":"1097_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/jnnp-2023-331941","volume":"95","author":"TE Goldberg","year":"2023","unstructured":"Goldberg TE, Lee S, Devanand DP, Schneider LS. Comparison of relative change with effect size metrics in Alzheimer\u2019s disease clinical trials. J Neurol Neurosurg Psychiatry. 2023;95:2\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01097-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:21:49Z","timestamp":1718608909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01097-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"13 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funded by UW Department of Neurology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Rosenbloom has served as a consultant for Eisai. Tricia O\u2019Doohue has no conflicts to declare. Lauren Shakalis has no conflicts to declare. Deepashni Mala has no conflicts to declare. Andrew Frazier has no conflicts to declare. Michael Tarrant has no conflicts to declare. Michelle Modrijan has no conflicts to declare. Melora Riveira has no conflicts to declare. Darla Chapman has no conflicts to declare. Yvonne Griffin has no conflicts to declare. Domi Zhou-Clark has no conflicts to declare. Thomas J. Grabowski has no conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Dr. Rosenbloom was the primary writer and contributor to the manuscript. Tricia O\u2019Donohue was part of the lecanemab implementation team. Lauren Shakalis was part of the lecanemab implementation team. Deepashni Mala was part of the lecanemab implementation team. Andrew Frazier was part of the lecanemab implementation team. Michael Tarrant was part of the lecanemab implementation team. Michelle Modrijan was part of the lecanemab implementation team. Melora Riveira was part of the lecanemab implementation team. Darla Chapman was part of the lecanemab implementation team. Yvonne Griffin was part of the lecanemab implementation team. Domi Zhou-Clark was part of the lecanemab implementation team and created figures for the manuscript. Thomas J. Grabowski reviewed and edited the manuscript. All authors have read and approve the final manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}